BIOCYTOGEN-B Shares Surge Over 4% in Morning Session on Explosive 2025 Profit Growth and BD Licensing Momentum

Stock News04-24

BIOCYTOGEN-B (02315) rose more than 4% during morning trading. At the time of writing, the stock was up 4.1% to HK$59.6, with a turnover of HK$26.46 million. The increase follows the company's release of its 2025 annual results, which showed revenue of RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to shareholders reached RMB 173 million, surging 416.37% year-on-year, while adjusted net profit was RMB 116 million, up 405.39%. After achieving its first profit turnaround in 2024, the company demonstrated explosive growth on the profit front in 2025. Analysts noted that with the divestment of capital-intensive self-developed clinical projects and the maturation of its "Thousand Mice Ten Thousand Antibodies" platform, BIOCYTOGEN-B has fundamentally transformed into a global foundational infrastructure leader for innovative drugs, characterized by ultra-high gross margins and strong positive cash flow. Looking ahead, the continued expansion of high-margin overseas operations and the expected realization of subsequent high-frequency business development collaborations are projected to provide sustained, robust long-term growth momentum for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174628270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 10:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174628270","market":"sh","top_or_hot":-1,"title":"BIOCYTOGEN-B Shares Surge Over 4% in Morning Session on Explosive 2025 Profit Growth and BD Licensing Momentum","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) rose more than 4% during morning trading. At the time of writing, the stock was up 4.1% to HK$59.6, with a turnover of HK$26.46 million. The increase follows the company's release of its 2025 annual results, which showed revenue of RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to shareholders reached RMB 173 million, surging 416.37% year-on-year, while adjusted net profit was RMB 116 million, up 405.39%. After achieving its first profit turnaround in 2024, the company demonstrated explosive growth on the profit front in 2025. Analysts noted that with the divestment of capital-intensive self-developed clinical projects and the maturation of its \"Thousand Mice Ten Thousand Antibodies\" platform, BIOCYTOGEN-B has fundamentally transformed into a global foundational infrastructure leader for innovative drugs, characterized by ultra-high gross margins and strong positive cash flow. Looking ahead, the continued expansion of high-margin overseas operations and the expected realization of subsequent high-frequency business development collaborations are projected to provide sustained, robust long-term growth momentum for the company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B Shares Surge Over 4% in Morning Session on Explosive 2025 Profit Growth and BD Licensing Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B Shares Surge Over 4% in Morning Session on Explosive 2025 Profit Growth and BD Licensing Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-24 10:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) rose more than 4% during morning trading. At the time of writing, the stock was up 4.1% to HK$59.6, with a turnover of HK$26.46 million. The increase follows the company's release of its 2025 annual results, which showed revenue of RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to shareholders reached RMB 173 million, surging 416.37% year-on-year, while adjusted net profit was RMB 116 million, up 405.39%. After achieving its first profit turnaround in 2024, the company demonstrated explosive growth on the profit front in 2025. Analysts noted that with the divestment of capital-intensive self-developed clinical projects and the maturation of its \"Thousand Mice Ten Thousand Antibodies\" platform, BIOCYTOGEN-B has fundamentally transformed into a global foundational infrastructure leader for innovative drugs, characterized by ultra-high gross margins and strong positive cash flow. Looking ahead, the continued expansion of high-margin overseas operations and the expected realization of subsequent high-frequency business development collaborations are projected to provide sustained, robust long-term growth momentum for the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1174628270","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174628270","pubTimestamp":1776998660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) rose more than 4% during morning trading. At the time of writing, the stock was up 4.1% to HK$59.6, with a turnover of HK$26.46 million. The increase follows the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4588":"碎股","02315":"百奥赛图-B","BK0216":"研究试验","VXUS":"国际股票ETF-Vanguard"},"translate_title":"由于2025年利润爆炸性增长和BD许可势头，百奥赛图-B股价早盘飙升超过4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"VXUS":1,"02315":1},"content_text":"BIOCYTOGEN-B (02315) rose more than 4% during morning trading. At the time of writing, the stock was up 4.1% to HK$59.6, with a turnover of HK$26.46 million. The increase follows the company's release of its 2025 annual results, which showed revenue of RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to shareholders reached RMB 173 million, surging 416.37% year-on-year, while adjusted net profit was RMB 116 million, up 405.39%. After achieving its first profit turnaround in 2024, the company demonstrated explosive growth on the profit front in 2025. Analysts noted that with the divestment of capital-intensive self-developed clinical projects and the maturation of its \"Thousand Mice Ten Thousand Antibodies\" platform, BIOCYTOGEN-B has fundamentally transformed into a global foundational infrastructure leader for innovative drugs, characterized by ultra-high gross margins and strong positive cash flow. Looking ahead, the continued expansion of high-margin overseas operations and the expected realization of subsequent high-frequency business development collaborations are projected to provide sustained, robust long-term growth momentum for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174628270","isCrawlerRequest":true}